Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 80

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 80
---
 pari passu to the Series E Preferred Stock) unless the Required Holders (as defined in the Fifth Securities Purchase
Agreement) consent to the creation of other capital stock of the Company that is senior or equal in rank to the Series E Preferred Stock.

Dividends. The holders
of Series E Preferred Stock will be entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends actually
paid on shares of the Common Stock, when and if actually paid.

Purchase Rights.
If at any time the Company grants, issues or sells any options, convertible securities, or rights to purchase stock, warrants, securities
or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the “Series E Purchase
Rights”), then each holder of Series E Preferred Stock will be entitled to acquire, upon the terms applicable to such Series E Purchase
Rights, the aggregate Series E Purchase Rights which such holder could have acquired if such holder had held the number of shares of Common
Stock acquirable upon complete conversion of all the Series E Preferred Stock (without taking into account any limitations or restrictions
on the convertibility of the Series E Preferred Stock and assuming for such purpose that all the Series E Preferred Stock held by such
holder were converted at the Series E Alternate Conversion Price (as defined below) in effect as of the applicable record date); subject
to certain limitations on beneficial ownership.

Conversion Rights

Conversion at Option of Holder. Each holder of Series E Preferred Stock may convert all, or any part, of the outstanding Series E Preferred Stock, at any
time at such holder’s option, into shares of the Common Stock (which converted shares of Common Stock are referred to as “Conversion
Shares” herein) at the fixed “Series E Conversion Price” of $4.1625, which is subject to proportional adjustment upon
the occurrence of any stock split, stock dividend, stock combination and/or similar transactions.

Voluntary Adjustment Right.
Subject to the rules and regulations of Nasdaq, the Company has the right, at any time after the Stockholder Approval Date (as defined
below), with the written consent of the Required Holders, to lower the fixed Series E Conversion Price to any amount and for any period
of time deemed appropriate by the Board of Directors.

Alternate Optional Conversion.
After the Stockholder Approval Date, at any time, at the option of the holder, the holder may convert the Series E Preferred Stock at
the “Series E Alternate